Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10658804 | 1.00 | GSR (0.55) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL10623775 | 1.00 | GSR (0.55) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL10658822 | 1.00 | GSR (0.55) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL2115366 | 0.97 | GSR (0.58) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL7781619 | 0.97 | GSR (0.58) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL1641744 | 0.97 | GSR (0.58) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL2115368 | 0.97 | GSR (0.58) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL17510190 | 0.97 | GSR (0.58) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL1641741 | 0.97 | GSR (0.58) | GSRDPP8DPP9DPP7GNAI3 | |
| SCHEMBL9705058 | 0.97 | GSR (0.58) | GSRDPP8DPP9DPP7GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119780188-A | Detection method of vancomycin | 新疆医科大学 | 2025-04-08 | — | — | CN | claimed |
| US-20220142477-A1 | Systems and Temporal Alignment Methods for Evaluation of Gestational Age and Time to Delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | US | claimed |
| US-12533389-B2 | Glycopeptide antibiotic combination therapy | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2026-01-27 | — | — | US | disclosed |
| WO-2025245227-A1 | BACTERIAL CELL WALL COMPONENTS AS PROBES FOR A LABEL-FREE BINDING ASSAY AND THE USE THEREOF | ACADEMIA SINICA (TW) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025229010-A1 | COMPOSITIONS COMPRISING DALBAVANCIN | HELM PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025229006-A1 | COMPOSITIONS COMPRISING DALBAVANCIN | HELM PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-12426782-B2 | Systems and temporal alignment methods for evaluation of gestational age and time to delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250288640-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250276065-A1 | Electro Magnetic Transducer Network in the Enhancement of Anti-infective Strategies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-04 | — | — | US | disclosed |
| WO-2024258613-A9 | TETRACHLOROVANCOMYCIN AND DERIVATIVES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-119780188-A | Detection method of vancomycin | 新疆医科大学 | 2025-04-08 | — | — | CN | disclosed |
| US-6392012-B1 | COMPOUND FOR USE IN TREATMENT AND PREVENTION OF BACTERIAL INFECTION | ADVANCED MEDICINE, INC. | 2002-05-21 | — | — | US | disclosed |
| EP-1140993-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Advanced Medicine, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1005356-A4 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE INC (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-1999064049-A9 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE INC (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-1060189-A1 | DERIVATIVES OF GLYCOPEPTIDE ANTIBACTERIAL AGENTS | Advanced Medicine, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000039156-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ADVANCED MEDICINE, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-1005356-A1 | NOVEL ANTIBACTERIAL AGENTS | Advanced Medicine, Inc. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999064049-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999042476-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288640-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, OGT, B3GNT2 | GSR 3752/4885DPP8 678/4885DPP9 313/4885 |
| US-12533389-B2 | Glycopeptide antibiotic combination therapy | VIP, MUC1, HSP90B1 | GSR 2787/4885DPP8 789/4885DPP9 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.